Our initial goal is to get FDA approval of Picoplatin and make it a (or the) preferred platinum-based drug in cancer treatment and to demonstrate the predictive capability of our genomic technology.

This will create a foundation of further development of the company, which is planned to be centered around rescue and repositioning of in-licensed underappreciated clinical assets, supplemented with our genomic technology.

The key elements of our clinical strategy in are:

•  Complete two Phase II clinical trials for Picoplatin for the purpose of defining and validating
   genomic     signatures of the Picoplatin response in patients with (a) squamous cell carcinoma of
   head and neck (or SCCHN) as well as (b) metastatic colorectal cancer (CRC).  (CRC is the third
   leading cause of cancer death in both men and women in the U.S. and the second leading cause
   of cancer death of men and women combined).
•  Following the completion of our Phase II trials, we plan to conduct a Phase III clinical trial for
   either or    both ijndications which will utilize these genomic classifiers to increase the patient
   response rate to Picoplatin.

Our midterm business strategy include:

•  Submission of application for registration of our drug  to the Ministry of Health of the Russian
   Federation for the right to market and sell Picoplatin for SCLC in the Russian Federation.
•  Seek a strategic partnership with a European partner to obtain European Union approval of
   Picoplatin for   SCLC.  (The European Commission designated Picoplatin as an orphan medicinal
   product for the treatment of   SCLC, which, if approved, would qualify Picoplatin for ten years of
   marketing exclusivity in the European Union)

•  Commercially Launch Picoplatin in the U.S.  Although we may decide to utilize a small specialty
   sales   strategy for targeting oncologists to launch Picoplatin if it is approved in the U.S., our
   primary focus will be   dedicated to entering into a partnership with a pharmaceutical company
   with an established sales force for the   full commercialization of Picoplatin and retaining a
   meaningful royalty percentage based upon U.S. sales

•  Pursue opportunities to develop and commercialize Picoplatin in foreign markets.  As we engage
   in clinical trials for Picoplatin in the U.S., we will also seek to enter into development and
   commercialization partnerships with pharmaceutical companies in foreign countries.

•  Leverage our genomic technology by acquiring rights to other compounds.  We will seek to in-
   license other drug compounds that we believe would be well-suited for our genomic technology.
   We believe that, once proved by our Picoplatin clinical trials, our genomics program has the
   potential to become a platform technology that could be used with other drug compounds